Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Gains from Investment Securities (2016 - 2025)

Historic Gains from Investment Securities for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to $1.4 million.

  • Protalix BioTherapeutics' Gains from Investment Securities rose 112795.76% to $1.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 16441.42%. This contributed to the annual value of $4.1 million for FY2024, which is 55351.33% up from last year.
  • According to the latest figures from Q3 2025, Protalix BioTherapeutics' Gains from Investment Securities is $1.4 million, which was up 112795.76% from $33000.0 recorded in Q1 2025.
  • Protalix BioTherapeutics' 5-year Gains from Investment Securities high stood at $1.4 million for Q3 2025, and its period low was -$556000.0 during Q2 2022.
  • In the last 5 years, Protalix BioTherapeutics' Gains from Investment Securities had a median value of $118000.0 in 2024 and averaged $266881.8.
  • Its Gains from Investment Securities has fluctuated over the past 5 years, first plummeted by 60545.45% in 2022, then soared by 112795.76% in 2025.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Gains from Investment Securities stood at $77000.0 in 2021, then surged by 1485.71% to $1.2 million in 2022, then tumbled by 85.91% to $172000.0 in 2023, then tumbled by 94.77% to $9000.0 in 2024, then skyrocketed by 15999.89% to $1.4 million in 2025.
  • Its Gains from Investment Securities stands at $1.4 million for Q3 2025, versus $33000.0 for Q1 2025 and $9000.0 for Q4 2024.